Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”

FDA has reported that the federal judge ordered a New Jersey company that sold injectable skin whitening and other beauty products to stop selling and recall some of its products because they are unapproved new drugs that may be unsafe, putting consumers at risk.

Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

Symcel, the company that makes assay tool for real-time cell metabolism measurements, calScreener – is expanding to bring its patented technology to the clinical antimicrobial susceptibility testing (AST) markets. The company states it

Adventist Health—a faith-based, nonprofit integrated health system serving more than 75 communities in California, Oregon and Hawaii—has received a positive outlook review from Fitch Ratings, Inc., one of the world’s leading financial ratings agencies.